The abbreviations used are: STAT: Signal transducer and activator of transcription, SHP-2: SH2 domain containing PTP-2; SHP-1: SH2 domain containing PTP-1; PTP: protein tyrosine phosphatase; DSP: dual-specificity phosphatase; SIE: c-sis inducible element; GST: glutathione S-transferase; MyBP: myosin binding protein; EGF, epidermal growth factor; IFN, interferon; pY, phospho tyrosine; pS, phospho serine.
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STAT proteins are latent cytoplasmic transcription factors, which can be activated by a variety of polypeptide hormones and cytokines. Activation of STAT proteins requires post-translational modification, i.e., phosphorylation at both tyrosine and serine residues.
Upon translocation into the nucleus, these proteins activate specific target genes by binding to regulatory sequences termed c-sis inducible elements (SIE). A variety of protein tyrosine kinases, transmembranal or non-transmembranal, such as JAK, EGFR and Src induce STAT tyrosine phosphorylation. Phosphorylation of the single tyrosine residue in the transcriptional activation domain of STAT is essential for STAT dimmer formation.
STAT serine phosphorylation, on the other hand, requires both ERK-dependent and independent activation pathways (1, 2) . Serine phosphorylation is critical for STAT to achieve full transcriptional activity even though it is not essential for STAT nuclear translocation and DNA binding. Thus, phosphorylation at both the positional conserved tyrosine and serine residues corresponding to Y701 and S727 of human Stat1 is required for its maximum transcription activity (3) . IFNγ activation of STAT proceeds to phosphorylate both tyrosine and serine residues and these two events appear to be independent of each other (4) . Jak1 and Jak2 functions are both required for IFNγ to induce Stat1 tyrosine phosphorylation. However, Jak2 has also been reported to be involved in Stat1 serine phosphorylation in response to IFNγ (5) . EGFR-activated STATs are also tyrosine and serine phosphorylated. Although associated with EGFR C-tail, JAKs are not involved in EGFR-mediated STAT activation (6, 7) .
STAT post-translational modification such as tyrosine and serine phosphorylation has been elegantly studied. The precise mechanism of the inactivation however has only recently begun to be uncovered. JAK specific inhibitors such as SOCS and inhibitors of activated STAT such as PIAS have been discovered (8, 9, 10) . STAT inactivation includes both maintaining STAT latency and terminating activated STAT by dephosphorylation.
Dephosphorylation however, may represent one of the most important mechanisms by which cells negatively control STAT activity. Treatment of cells with protein tyrosine by guest on http://www.jbc.org/ Downloaded from phosphatase (PTP) inhibitors such as vanadate leads to STAT activation, indicating that PTP(s) is required for maintaining STAT in its inactive form. Upon cytokine or growth factor stimulation, STATs are rapidly phosphorylated at both tyrosine and serine residues and bind DNA, which is followed by gradually STAT dephosphorylation and dissociation from DNA. Phosphatases therefore control STAT activity at two levels: (i) by maintaining STAT in its latent form by blocking phosphorylation and; (ii) by terminating STAT activity by removing available phosphates. It suggests that the balance between protein kinases and protein phosphatases play an important role in modulating the activity of STATs in vivo (11, 12) . The protein phosphatases responsible for STAT dephosphorylation in nucleus has yet to be confirmed (13) .
The present study was set out to identify the protein phosphatase(s) responsible for STAT dephosphorylation in nuclei. By employing our novel antibody array screening for protein-protein interaction, we identified SHP-2 and Stat1 association in A431 cells.
Treatment of A431 cells with either EGF or IFNγ led to Stat1 and SHP-2 accumulation in
nucleus where these two proteins interact with each other within their C-terminal regions.
We provide evidence here that SHP-2 is a dual-specificity protein phosphatase involved in Stat1 dephosphorylation at both pY701 and pS727 residues.
Materials and Methods

Constructs, cells, and cell lysates.
Recombinant proteins: cDNA of Full length SHP-2 (amino acid residues 1 -593), N-SH2 domain (residues 1 -107), C-SH2 domain (residues 108 -220), N-SH2-C-SH2
(residues 1 -220), C-SH2PTP (residues 108 -593), or PTP domain (residues 221 -593) was inserted at the 3' end and in frame to the GST ORF in the expression vector pGEX-3T (Pharmacia Biotech). Bacterially expressed GST-fusion proteins were purified using Glutathione agarose beads (Sigma) and dialyzed overnight. Human Stat1 cDNA of full length (residues 1 -750), C-terminal (residues 489 -750), N-terminal (residues 1 -488), by guest on http://www.jbc.org/ Downloaded from and SH2-TA domain (residues 577 -750) were tagged with His6 by inserting them into pET28A vector respectively. Expression of recombinant His6-Stat1 proteins was confirmed by immunoblotting using both anti-His6 and anti-Stat1 antibodies. SH-2-/-and control mouse fibroblasts (14) were maintained in DMEM supplement with 10% fetal bovine serum.
Cell lines and preparation of cell extracts: A431 cells, 293T cells, and both SHP-2-/-and control mouse fibroblasts were maintained in DMEM supplied with 10% FBS.
Whole cell lysates were prepared by using RIPA buffer (1xPBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) with proteinase inhibitors (0.5 mM PMSF, 1µg/ml each of aprotinin, pepstatin, and leupeptin; and 1 mM DTT) freshly added as described previously (15, 16) . The cytoplasmic fraction was prepared by lysing cells in Hepes buffer (20mM, pH 7.9, 10 mM KCl, 1mM EDTA, 10% glycerol) with DTT and the above inhibitors freshly added. After a brief centrifugation, the supernatants were collected as cytoplasmic lysates. The nuclear fraction was obtained by resuspending the crude nuclei in 420 mM NaCl for 30 min, and the supernatants were collected after centrifugation at 10,000x g for 5 min (17) . All the steps were carried out at 4 o C.
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In vitro STAT dephosphorylation assays.
Phospho-Stat1 was immunopurified from IFNγ -treated SHP-2-/-fibroblasts by using the rabbit polyclonal antibody specifically against pY701-Stat1. Such immunoprecipitated phospho-Stat1 was then incubated with GST-SHP-2 in the Hepes reaction buffer buffer (25 mM Hepes, pH 6.5, 50 mM NaCl, and 10 mM 2-mercapetoethanol) for 10 min at room temperature followed by boiling in 2x loading buffer for 5 min. The boiled samples were then analyzed in immuno-blot. When synthesized phospho-peptides were used as the substrate, Malachite green assay was performed to detect released inorganic phosphate (Pi) as described elsewhere (18, 19 Immuno-precipitation, SDS-PAGE electrophoresis, and immuno-blotting assays were performed essentially as described previously (12, 16, 17) . were also incubated with 1 ng 32 P-labeled M67-SIE double strand oligo for 10 min and analyzed on an electrophoretic mobility shift assay (EMSA) gel as described previously (17) . For Stat1-dependent reporter assay, 293T cells were plated in 6-well dishes with 50% confluence the day before transfection. hrs, the cells were harvested in PBS and lysed in luciferase lysis buffer (Promega). The lysates were assayed for luciferase activity using an OPTOCOMP I Luminometer.
Results
Stat1 and SHP-2 association identified by antibody array assay.
To evaluate the process of STAT protein dephosphorylation in vivo, we first treated A431 cells with EGF and IFNγ for different times and activated Stat1 proteins were immunoprecipitated by using antibodies recognizing pY701-Stat1 and pS727-Stat1 respectively. As shown in Fig. 1A , both EGF and IFNγ induced rapid Stat1 phosphorylation on both Y701
and S727 residues. Twenty-four hrs later, tyrosine phosphorylated Stat1 was still detectable in the cells treated with IFNγ , but completely disappeared in the cells treated with EGF.
Under the same conditions, serine dephosphorylation at pS727 was slower compared with tyrosine dephosphorylation at pY701 residue ( 
Stat1 and SHP-2 nuclear translocation in response to EGF and IFN .
To assess the location where SHP-2 interacts with Stat1, we examined their subcellular localization in cells. We probed A431 cells with Stat1-and SHP-2 specific IgG respectively in immuno-fluorescence experiments. Both EGF-and IFNγ -mediated Stat1 nuclear translocations were immediately observed ( Fig. 2A ). SHP-2 distributed in both nuclei and cytoplasm prior to stimulation. Anti-SHP-2 antibody stain the nuclei intensely in both EGF-and IFNγ -treated cells, although some punctuate cytoplasmic staining could also be seen ( Fig. 2A) . We then evaluated the kinetics of these two proteins in nuclear translocation. EGF treatment increased both SHP-2 and Stat1 steady nuclear migration 10 within a period of 30 min to 6 hrs ( Fig. 2B ). SHP-2 nuclear translocation time course has been repeated at least three times and about 2-3 folds increase of SHP-2 level in nuclei was detected after EGF treatment for 6 hrs. While nuclear phospho-Stat1 was stable for at least 6 hrs, SHP-2 nuclear level was steadily increased up to 3 hrs but restored to the basal level after 6 hrs of treatment ( Fig.2B low panel) . In Stat1-deficient cell line U3A SHP-2 nuclear localization was detected, which was not dependent on IFNγ -treatment (data not shown).
Consistently, more Stat1/SHP-2 protein complexes were detected in the nuclear fraction of EGF-treated than that of IFNγ -treated A431 cells (Fig. 2C ). Both EGFR and Jak1 were recovered from SHP-2 immuno-precipitates in the cytosolic fractions ( Fig. 2E , middle panels). Another JAK family member Jak2 was not found to associate with SHP-2 (data not shown). Although SHP-2 can block STAT activation via inhibiting JAK activity in cytoplasm as reported previously (14), the above results indicate that SHP-2 may directly affect Stat1 activity in nuclei.
Stat1 C-terminal SH2-TA domain interacts with SHP-2 C-terminal PTP domain.
To characterize the domains of SHP-2 and Stat1 involved in their direct interaction, we generated a number of GST recombinant fusion proteins of SHP-2 either in full length or in different functional domains as indicated in Fig. 3A . Equal amounts of different GST-SHP-2 fusion proteins bound to Glutathione-Sepharose beads were incubated with A431 whole cell lysates, and proteins interacting with the GST fusion proteins analyzed by anti-Stat1 immuno-blotting assay. As shown in Fig. 3A , GST-PTP, GST-SH2N-PTP, and GST-SHP-2 of full length, containing C-terminal region (residues 217 -593) could pull down Stat1. The N-terminal region of SHP-2 (residues 1 -220) comprising 2 tandem SH2 domains is important for both protein-protein interaction and C-terminal PTP regulatory actions (21, 22, 23) . However, our results revealed that neither these individual 220) was able to precipitate Stat1 (Fig. 3A) . A weak signal was visible after extended exposure time, indicating that a weak interaction between Stat1 and SH2C-SH2N domain of SHP-2 occurred. These data indicate that the SHP-2 C-terminal catalytic domain (PTP)
mediates its interaction with Stat1. We next sought to delineate the region(s) of Stat1 important for its interaction with SHP-2. This was accomplished using His6-Stat1 in full length or truncated forms as indicated in Fig. 3B . These His6 recombinant Stat1 proteins were incubated with A431 cell extracts followed by SHP-2 antibody immuno-precipitation.
SHP-2 immuno-precipitates were subsequently analyzed by immuno-blotting with antiHis6 antibody. Results in Fig. 3B showed that full length His6-Stat1 (His-Stat1), the Cterminal region His6-Stat1 (His-C-Stat1, residues 468 -750), and SH2-TA domain His6-Stat1 (His-SH2TA, residues 577 -750) all pulled down SHP-2. No significant amount of His6-N-Stat1 representing the relatively conserved N-terminal region of Stat1 (residues 1 -467) was present in the SHP-2 precipitate (Fig. 3B ).
SHP-2 was shown to interact with JAK and other cellular component (24) . To ascertain whether the interaction between the C-regions of these two proteins revealed in GST, GST-PTP, and full length GST-SHP2 followed by immuno-analysis with anti-Stat1.
As shown in Fig. 3C , all the three forms of His6-Stat1 could form complexes with both full length GST-SHP-2 and GST-PTP, but not with GST. Consistent with the results in Fig.3A and 3B, the interaction between His-Stat1 N-region and GST-PTP or full length GST-SHP-2 were not detected ( Fig. 3C right panel) . The importance of different motifs of Stat1 in interaction with SHP-2 was then examined in 293T transfectants. Stat1 with Y701F, S727A, or DBD (E428E429-AA) mutation could still interact with SHP-2 ( Fig.3D ). Stat1 with a deletion mutation from S316 to S606 was constructed, with which whole linker domain (residues T489 -G576), the critical motif (E428E429) of DNA 12 binding domain (residues F318-L488), and the essential part of SH2 domain (SH2 starts from C577) were removed. As can be seen clearly in Fig 3D, this short form of Stat1 still interacted with SHP-2. These in vivo findings were consistent with the in vitro studies that Stat1 and SHP-2 interaction occurred directly within their C-terminal domains, irrelevant to their SH2 domains. A direct interaction between SHP-2 catalytic domain (C-region) and Stat1 C-region containing both phosphotyrosine and phosphoserine residues required for transcription activity strongly suggests that SHP-2 can directly dephosphorylate Stat1.
SHP-2 is a dual specificity protein phosphatase dephosphorylating Stat1 at both Y701 and S727 residues.
To determine whether SHP-2 dephosphorylates Stat1, IFNγ -induced Stat1 phosphorylation/ dephosphorylation was evaluated in SHP-2-/-and control fibroblasts. (14) . Similarly, Stat1 serine phosphorylation at S727 by IFNγ was also greatly enhanced and prolonged in SHP-2-/-fibroblasts (Fig. 4A) . As expected, Stat1 tyrosine and serine phosphorylations were much weaker in SHP-2 reintroduced SHP-2-/-cells (Fig.4A) . To further confirm a direct role of SHP-2 on Stat1 dephosphorylation, SHP-2-/-and control cells were treated with IFNγ for 2 hrs, and then kinase activity was halted by adding the kinase inhibitor genistein. Phospho-Stat1 level was quite stable for 3
hrs and was only weakly reduced after 6 hrs in SHP-2-/-cells. In control cells, phosphoStat1 was about the same for the first hour after genistein treatment. However,
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after an additional hour or so, phosphoStat1 level decreased by at least one-half and the signal disappeared almost completely within 6 hrs of genistein treatment (Fig.4B) .
We then compared Stat1 DNA binding activity in SHP-2-/-with control fibroblasts.
Cell lysates prepared from these fibroblasts were incubated with SIE-agarose beads. Stat1 precipitation by SIF oligos was then confirmed in immuno-blotting. As expected, in SHP-2-/-cells, Stat1 DNA binding activity was greatly enhanced and prolonged (Fig. 4C) , whereas in control cells, Stat1 DNA binding activity was transiently induced by IFN−γ.
Published work showed already that in these mutant cells reconstituted with wild type SHP-2, STAT activation by IFN was no longer enhanced or prolonged (14) . These results indicate that SHP-2 specifically affects Stat1 protein phosphorylation at both tyrosine and serine residues in cells.
Elevated Jak1 tyrosine phosphorylation in this SHP-2 mutant cell line has been previously reported (14) . The augmented and prolonged Stat1 activation observed here could be the consequence of enhanced Jak1 activity. We fractionated the cytosolic and nuclear lysates from the SHP-2-/-embryonic fibroblasts treated with IFNγ for different times. As shown in Fig. 4D , constitutively phosphorylated Jak1 was detected in both cytosolic and nuclear fractions. As expected, Jak1 phosphorylation in response to IFNγ treatment for 30 min was enhanced in the cytosole fraction. IFNγ -induced Jak1 tyrosine phosphorylation was transient and decayed rapidly. Similarly, Jak1-Stat1 complex formation in the cytoplasm was also transient and quickly dissociated. Although both were detected in nucleus, Jak1 and phosphoStat1 did not form complexes (Fig.4D) . Thus, elevated Jak1 activation in cytoplasm in SHP-2-/-cells was unlikely responsible for prolonged Stat1 activation in these cells. We then examined the stature of another STAT family member, Stat5, in this SHP-2 mutant cell line. Stat5 was constitutively tyrosine phosphorylated in both SHP-2-/-and control fibroblasts (Fig. 4E) . Fig.5B) . Sodium orthovanadate (Na 3 VO 4 ), an nonspecific PTP inhibitor, blocked GST-SHP-2 activity in dephosphorylating Stat1 at both Y701 and S727 residues further support the notion that protein tyrosine phosphatase activity was involved in the above in vitro assays in Fig.5C .
The specificity of Stat1 as a substrate of SHP-2 was also evaluated by using phospho-peptide representing the Y701 motif of Stat1 as substrate in a Malachite Green assay. Synthesized phosphopeptides were incubated with GFT-SHP-2 and Malachite
Green solution was added to stop the reaction. Released Pi level was measured at 620 nm as described (18, 19) . GST-SHP-2, but not GST-SHP-2 with C459->S mutation or GST control protein, induced rapid Pi release from this pTyr-peptide as reflected by the increase in absorbance at 620 nm (Fig. 5D) . Structurally, both SHP-2 and SHP-1 share the activesite sequence motif "HCXXXXXRT/S" with most of dual-specificity phosphatases (DSP)
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http://www.jbc.org/ Downloaded from ( Fig.5E ) (26, 27) . Virtually, all PTP and DSP contain an essential cysteine. At secondary structure level (Fig.5E ), no apparent difference was observed in this region between these two groups of phosphatases.
When pSer-peptide representing Stat1 S727 residue was used as the substrate, GST-SHP-2 was capable of catalyzing Pi release but with less efficiency (Fig.5D ). It is typically true for most of dual-specificity protein phosphatases that their intrinsic serine dephosphorylation activities are much weaker compared with their intrinsic tyrosine dephosphorylation activities (20) . To prove further that SHP-2 dephosphorylates phosphoserine, radioactive protein serine phosphatase (PSP) assay was performed. MyBP was labeled at multiple serine residues with 32 P-ATP by protein kinase A (PKA) and was used as a model substrate. Upon treatment of 32 P-Serine-MyBP with GST-SHP-2 but not GST control protein, a substantial release of radiolabeled Pi was immediately detected in scintillation counting solution ( Fig.5F and G). Free PO4 release was both substrate (i.e., MyBP) concentration and enzyme (i.e., SHP-2) concentration dependent. Neither GST control protein nor GST-SHP-2 with C459S mutation showed any effect on Pi release from 32 P-Serine-MyBP, which excludes the possible contamination of an bacterial serine phosphatase activity in GST fusion proteins. Compared to HVH1, a previously demonstrated DSP (28), similar range of serine dephosphorylation was obtained in response to GST-SHP-2 when MyBP was used as the substrate (Fig.5G ). His6-tailed peptide containing Stat1 S727 residue was synthesized and labeled with 32 P by Erk2. After incubation with GST-SHP-2 for 15 min, Ni 2+ -NTA precipitated 32 P-peptides were washed and counted in scintillation solution. GST-SHP-2, not the one with C495S mutation or GST control protein, greatly diminished cpm counting associated with Ni2+-NTA beads (Fig.5H) . These findings strongly indicate that SHP-2 is a DSP, which can dephosphorylate both phosphotyrosyl and phosphoseryl residues. Although both Stat1 and IFNγ R are substrates of Jak1, lack of functional SHP-2 showed no effect on IFNγ R tyrosine phosphorylation in response to IFNγ in SHP-2-/-mouse fibroblast (14) . Consistently, IFNγ R tyrosine phosphorylation and its Stat1 recruitment activity in response to IFNγ stimulation were not impaired in 293T cells transfected with SHP-2 ( Fig. 6B top 3 panels). Whereas, nuclear phosphoStat1 level in 293T cell transfected with wild type SHP-2, but not C459S SHP-2, was reduced. Jak2
was reported as the substrate of SHP-1, an analogous variant of SHP-2 (11, 23) . In contrast, Jak2 activity was up regulated rather than down regulated by SHP-2 (14, 29) . In 293T cell nuclei however, neither Jak2-Stat1 nor Jak2-SHP-2 complex was detected (not shown). Together, these results indicate that SHP-2 directly can inactivate nuclear Stat1 and terminate Stat1 activity for gene regulation.
Discussion
Based on the above results, we conclude that SHP-2 is a DSP to dephosphorylate Stat1 at both pY701 and pS727 residues. Recent studies implicate that SHP-2 is tightly involved in the modulation of cytokine-stimulated JAK and/or STAT activities (14, 24, 30 (14) . In SHP-2-/-fibroblasts, Jak1 tyrosine phosphorylation was transiently augmented in response to IFNγ , which led to a transient complex formation between Jak1 and Stat1. However, tyrosine phosphorylation of IFNγ R by JAK was neither augmented in SHP-2-/-fibroblasts (14) nor reduced in SHP-2 transfected 293T cells (Fig.6C) . Moreover, immunoprecipitated Stat1 can be dephosphorylated by GST-SHP-2 in vitro. All these results suggest that SHP-2's involvement in phospho-Stat1 inactivation. Thus, SHP-2 regulates Stat1 activity at least at two levels, i.e., blocking JAK tyrosine kinase activity and removing phosphate group from phospho-Stat1.
To reach full activation of transcription, STAT needs to be both tyrosine and serine phosphorylated. Serine phosphorylation/dephosphorylation in nucleus provides a more delicate regulation of STAT activity in transcription. SHP-2 was capable of dephosphorylating Stat1 at both pTyr and pSer residues in vitro, consistent with the fact that in SHP-2-/-fibroblasts, Stat1 tyrosine and serine phosphorylations were both prolonged. Both MAP kinase (Erk) and Jak2 were related to STAT serine phosphorylation previously (1, 2, 5). Unlike Jak-1, MAP kinase (Erk) activity was significantly decreased in SHP-2-/-cells, suggesting a positive effect of SHP-2 on MAP kinase (25, 31) .
Stimulatory effect of SHP-2 on Jak2 activity was also reported (29, 32) . Therefore, the negative effect of SHP-2 on Stat1 was unlikely mediated by these proteins in nucleus. Like most DSPs, the catalytic activity of SHP-2 in serine dephosphorylation was much lower compared with its intrinsic catalytic activity in tyrosine dephosphorylation. This is probably due to the catalytic cleft of SHP-2 and perhaps all DSPs is too deep to be able to accept a pSer residue and hydrolyze it efficiently. It may explain why Stat1 serine phosphorylation was greatly prolonged in vivo ( Fig.1 and Fig.4 ).
Previous studies showed that enhanced tyrosine phosphorylation and DNA binding activity were observed with either N-terminal or C-terminal deleted STATs (33, 34) .
However, our in vitro protein-protein interaction studies revealed that SHP-2 associated with Stat1 only within its C-terminal region containing SH2-TA domain and both Y701 and immuno-precipitates were subjected to immunoblot with anti-Stat1 or anti-SHP-2 antibody as indicated. In the bottom two panels, reversed immunoprecipitation/blot was performed.
Anti-Stat1 immuno-precipitates from A431 cell lysates were subjected to anti-SHP-2 and anti-Stat1 immuno-blotting as indicated. Three-dimensional structure of SHP-2 obtained from crystallographic study was given 
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